NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  

Rediff News  All News  » Business » Scottish company looks to India for clinical research

Scottish company looks to India for clinical research

Last updated on: March 28, 2006 14:36 IST

Scotland-based clinical research organisation Drug Development Solutions Ltd Monday said it is in talks with leading Indian pharmaceutical companies, including Ranbaxy and Dabur, for collaboration in drug research and it is scouting for partnership with Indian data management companies.

"In India we are looking for collaboration in two areas. One, with pharmaceutical companies for clinical pharmacology research and the other for partnership or joint ventures with data management or biostatistics companies for data management," Drug Development Solutions CEO and Medical Director Brian Sanderson told PTI.

He said DDS was currently in talks with Ranbaxy Laboratories, Dabur Pharma and GVK Biosciences for collaboration in areas of clinical pharmacology.

"We have had talks with these companies for collaboration in areas like drug photosensitivity research, first-in-man (Phase I) study and drug interaction studies," Sanderson said.

On DDS' plans for partnership in India with data management and biostatistics companies, he said, "This is a priority area and we are looking out for partnership or a joint venture with Indian company who can manage the data for our clients."

By the end of the year, the company expects to have a partnership or a joint venture in place, he added.

The 3-million pound (about Rs 23.4 crore) company is expecting to touch a revenue of around 5 million pounds (about Rs 39 crore) in the next five years.

"We expect to have a business of nearly half a million pounds (about Rs 4 crore) from the Indian operations in two years if things go as planned," he said.


© Copyright 2018 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.